Bal Pharma Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Limited has informed NSE and BSE that filing a statement of deviation or variation in utilization of funds is not applicable for the quarter ended March 31, 2026. The company clarifies that it has not raised any funds through public issue, rights issue, preferential issue, QIP, or any other mode during this period. Additionally, there are no proceeds from earlier issues that remain outstanding for utilization. This is a routine compliance filing under Regulation 32(1) of SEBI (LODR) Regulations, 2015, simply stating non-applicability of the reporting requirement.
No immediate impact on shareholders as this filing confirms zero fund-raising activity and no outstanding proceeds requiring tracking. The company remains in compliance with regulatory requirements by making the required disclosure.